Loading…
Uses AI and lab automation to discover antibodies for pharma partners and its own drug pipeline.
Uses AI and lab automation to discover antibodies for pharma partners and its own drug pipeline.
Earns research fees, milestones and royalties from partners that use its platform to find antibodies, and invests in its own drug candidates. Its income spiked in 2021 on royalties from the COVID antibody it helped find for Lilly, and has since come from smaller partner programmes while it builds its own pipeline.
In one line: A discovery-stage biotech, like Moderna but for antibodies rather than mRNA.
Moat: narrow (data, IP / patents, process know-how). Large proprietary antibody discovery database and high-throughput screening platform.
Headquarters: Vancouver, Canada · Founded: 2012 · Employees: 562
Size AbCellera Biologics (ABCL) is a United States Health Care company (Biotechnology) with a market value of $3.85B, the 1374th largest of 3,117 United States companies the cockpit tracks. Shares closed at $6.93 on 6 Nov 2026.
Performance Over six months the shares gained 149.3%, against +0.8% for the median peer and -1.1% for the United States market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue grew 101.3% over the last twelve months (peer median +8.3%); the operating margin is -340.2% (peer median -63.1%).
Valuation It trades at 51.7× enterprise value to sales against a peer median of 14.9× (5th most expensive of 17).
Capital Return on invested capital runs 50.7 points below its cost of capital (12.6% WACC).
Backlog Backlog (remaining performance obligations) was $56.0M at 30 Jun 2026. Backlog detail →
Short interest Short interest is 9.6% of the free float (15 Oct 2026).
Next results Next results expected around 9 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $66.2M | $75.1M | $28.8M | $38.0M | $485M |
| Revenue growth | — | +161% | -24% | -92% | — |
| Gross profit | $33.6M | $46.3M | -$68.2M | $7.13M | n/a |
| EBITDA | -$193M | -$188M | -$218M | -$206M | $316M |
| Net income | -$165M | -$146M | -$163M | -$146M | $159M |
| Free cash flow | -$119M | -$174M | -$187M | -$121M | $207M |
| Capital expenditure | $24.4M | $42.8M | $78.4M | $77.5M | $72.7M |
| Total debt | $136M | $143M | $65.4M | $77.4M | $82.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| AbCellera Biologics ABCL | $3.85B | +149% | +101% | -340% | 51.7× | n/a |
| Twist Bioscience TWST | $7.95B | +112% | +19% | -32% | 18.2× | n/a |
| Absci ABSI | $1.75B | +72% | -62% | -8,411% | 991.7× | n/a |
| OmniAb OABI | $734M | +29% | +91% | -116% | 17.1× | 59.6% |
| Evotec EVT.DE | $630M | -33% | -8% | -19% | 0.8× | n/a |
| Charles River Laboratories CRL | $16.1B | +90% | -1% | 15% | 4.7× | 25.3% |
| Genscript Biotech 1548.HK | $8.81B | +96% | +53% | 12% | 9.9× | 36.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ABCL | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.9% | +2.7% | 7th lowest of 21 |
| 6-month return | +149.3% | +0.8% | highest of 21 |
| Distance from 52-week high | -17.9% | -26.8% | 5th highest of 21 |
| Revenue growth (TTM) | +101.3% | +8.3% | 2nd highest of 16 |
| Operating margin | -340.2% | -63.1% | 5th lowest of 17 |
| EV / Sales | 51.7× | 14.9× | 5th most expensive of 17 |
| ROIC minus cost of capital | -50.7 pp | -14.0 pp | 4th lowest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| AbCellera Biologics ABCL | United States | $3.85B | +149% | +101% | -340% | 51.7× | n/a | n/a |
| Beijing Tiantan Biological Products 600161.SS | China | $3.76B | -11% | -13% | 21% | 4.8× | 3.2% | +12.5% |
| Lin BioScience 6696.TWO | Taiwan | $3.74B | +129% | n/a | n/a | n/a | n/a | n/a |
| Iovance Biotherapeutics IOVA | United States | $3.64B | +64% | +35% | -91% | 10.4× | n/a | n/a |
| Relay Therapeutics RLAY | United States | $4.08B | +46% | +24% | -2,999% | 308.8× | n/a | n/a |
| Tango Therapeutics TNGX | United States | $3.63B | -7% | +121% | -253% | 49.1× | n/a | n/a |
| Enliven Therapeutics ELVN | United States | $3.62B | +21% | n/a | n/a | n/a | n/a | n/a |
| Disc Medicine IRON | United States | $3.50B | +16% | n/a | n/a | n/a | n/a | n/a |
| Virbac VIRP.PA | France | $3.38B | +5% | +4% | 15% | 2.1× | 6.2% | +9.4% |
| Dyne Therapeutics DYN | United States | $3.37B | +3% | n/a | n/a | n/a | n/a | n/a |
| Hualan Biological Engineering 002007.SZ | China | $3.37B | -15% | -11% | 17% | 5.6× | 16.7% | -1.8% |
| XtalPi 2228.HK | Hong Kong | $3.35B | -34% | +4% | -127% | 26.3× | n/a | n/a |
| JOINN Laboratories (China) 6127.HK | Hong Kong | $4.43B | +9% | +17% | -4% | 15.1× | n/a | n/a |
| Adaptive Biotechnologies ADPT | United States | $4.47B | +103% | +50% | -12% | 14.7× | n/a | n/a |
| Changchun High-Tech Industry (Group) 000661.SZ | China | $4.51B | -13% | -18% | -1% | 2.8× | 32.2% | +7.1% |
| Telix Pharmaceuticals TLX.AX | Australia | $3.22B | -6% | +27% | -1% | 3.9× | n/a | n/a |
| Denali Therapeutics DNLI | United States | $3.22B | +2% | n/a | -2,488% | 128.0× | n/a | n/a |
| Beijing Wantai Biological Pharmacy Enterprise 603392.SS | China | $4.72B | -37% | +8% | -35% | 14.5× | n/a | n/a |
| Dianthus Therapeutics DNTH | United States | $4.81B | -1% | -61% | -11,441% | 2,087.9× | n/a | n/a |
| HLB 028300.KS | South Korea | $3.06B | -49% | +29% | -96% | 45.9× | n/a | n/a |
| CRISPR Therapeutics CRSP | United States | $4.86B | -9% | -34% | -2,059% | 133.6× | n/a | n/a |
AbCellera Biologics reported $56.0M of remaining performance obligations at 30 Jun 2026.